US

Uciane Scarlett

Stealth

Cambridge, Massachusetts

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

2025

  • Stealth

    2025

2021 - 2024

  • Principal

    2021 - 2024

    Fund management - oversaw INV fund ($100M) Company Creation/Operations/Financing: ashibio (Head Corp Dev), Crane BioTherapeutics (interim CEO) Boards: Crane BioTherapeutics, TUO Therapeutics, ProRavel

  • Principal

    2019 - 2021

    Fund management - co-lead life science vertical (2/3 of fund), company creation, portfolio management Company Creation/Operations/Financing: T-Cypher Bio (interim Exec Chair), PepGen, ORFonyx, Alethiomics, Endlyz Boards: T-Cypher Bio, PepGen (NASDAQ: PEPG), Miro Bio (acq. by Gilead), DJS (acq. by AbbVie), Scenic Bio

2018 - 2019

  • Associate

    2018 - 2019

    Life science investing, company creation, portfolio company operations. Company Creation/Board: Dyne Therapeutics, Quench Bio, Navitor Operations: Dyne Therapeutics, Quench Bio, Korro Bio, AVRO BIO

  • Director of Business Development & Strategy

    2016 - 2018

    Drove business development & corporate/pipeline strategy; participated in venture financing; conceptualized strategic academic partnership; presented to BoD; engaged with various bankers, analysts, VCs

  • Manager | Consultant | Associate

    2011 - 2016

    Corporate/pipeline strategy, early commercial strategy, business development; strong oncology focus Drove internal initiatives geared towards growing Clarion's oncology business Published two articles (business journal & peer-reviewed journal) in oncology

2011 - 2011

  • Postdoctoral Fellow

    2011 - 2011